|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RHEX |
Gene summary for RHEX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RHEX | Gene ID | 440712 |
| Gene name | regulator of hemoglobinization and erythroid cell expansion | |
| Gene Alias | C1orf186 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0002262 | UniProtAcc | Q6ZWK4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 440712 | RHEX | CA_HPV_1 | Human | Cervix | CC | 9.60e-24 | -5.54e-01 | 0.0264 |
| 440712 | RHEX | CA_HPV_3 | Human | Cervix | CC | 2.49e-03 | -2.91e-01 | 0.0414 |
| 440712 | RHEX | N_HPV_2 | Human | Cervix | N_HPV | 1.41e-07 | -4.10e-01 | -0.0131 |
| 440712 | RHEX | CCII_1 | Human | Cervix | CC | 5.19e-11 | -6.11e-01 | 0.3249 |
| 440712 | RHEX | Tumor | Human | Cervix | CC | 1.05e-26 | -6.11e-01 | 0.1241 |
| 440712 | RHEX | sample1 | Human | Cervix | CC | 8.75e-07 | -6.00e-01 | 0.0959 |
| 440712 | RHEX | sample3 | Human | Cervix | CC | 1.36e-12 | -4.01e-01 | 0.1387 |
| 440712 | RHEX | H2 | Human | Cervix | HSIL_HPV | 5.94e-05 | -1.95e-01 | 0.0632 |
| 440712 | RHEX | L1 | Human | Cervix | CC | 3.29e-12 | -6.11e-01 | 0.0802 |
| 440712 | RHEX | T1 | Human | Cervix | CC | 3.09e-16 | -5.95e-01 | 0.0918 |
| 440712 | RHEX | T3 | Human | Cervix | CC | 3.68e-15 | -3.48e-01 | 0.1389 |
| 440712 | RHEX | AEH-subject1 | Human | Endometrium | AEH | 1.17e-141 | 1.99e+00 | -0.3059 |
| 440712 | RHEX | AEH-subject2 | Human | Endometrium | AEH | 4.49e-97 | 1.78e+00 | -0.2525 |
| 440712 | RHEX | AEH-subject3 | Human | Endometrium | AEH | 5.61e-129 | 1.90e+00 | -0.2576 |
| 440712 | RHEX | AEH-subject4 | Human | Endometrium | AEH | 1.16e-90 | 1.79e+00 | -0.2657 |
| 440712 | RHEX | AEH-subject5 | Human | Endometrium | AEH | 2.16e-146 | 2.15e+00 | -0.2953 |
| 440712 | RHEX | EEC-subject1 | Human | Endometrium | EEC | 5.60e-157 | 2.29e+00 | -0.2682 |
| 440712 | RHEX | EEC-subject2 | Human | Endometrium | EEC | 1.93e-158 | 2.10e+00 | -0.2607 |
| 440712 | RHEX | EEC-subject3 | Human | Endometrium | EEC | 1.03e-53 | 1.37e+00 | -0.2525 |
| 440712 | RHEX | EEC-subject4 | Human | Endometrium | EEC | 8.11e-109 | 1.82e+00 | -0.2571 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:190370610 | Cervix | CC | regulation of hemopoiesis | 80/2311 | 367/18723 | 2.14e-07 | 9.55e-06 | 80 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
| GO:003021810 | Cervix | CC | erythrocyte differentiation | 34/2311 | 120/18723 | 2.00e-06 | 6.18e-05 | 34 |
| GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
| GO:004563710 | Cervix | CC | regulation of myeloid cell differentiation | 48/2311 | 210/18723 | 1.49e-05 | 2.93e-04 | 48 |
| GO:00456468 | Cervix | CC | regulation of erythrocyte differentiation | 17/2311 | 47/18723 | 2.38e-05 | 4.16e-04 | 17 |
| GO:00456397 | Cervix | CC | positive regulation of myeloid cell differentiation | 28/2311 | 103/18723 | 3.56e-05 | 5.70e-04 | 28 |
| GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
| GO:00456483 | Cervix | CC | positive regulation of erythrocyte differentiation | 12/2311 | 33/18723 | 3.53e-04 | 3.68e-03 | 12 |
| GO:003009915 | Cervix | HSIL_HPV | myeloid cell differentiation | 36/737 | 381/18723 | 1.19e-06 | 5.62e-05 | 36 |
| GO:190370613 | Cervix | HSIL_HPV | regulation of hemopoiesis | 35/737 | 367/18723 | 1.35e-06 | 6.21e-05 | 35 |
| GO:004563715 | Cervix | HSIL_HPV | regulation of myeloid cell differentiation | 22/737 | 210/18723 | 2.97e-05 | 8.57e-04 | 22 |
| GO:000226215 | Cervix | HSIL_HPV | myeloid cell homeostasis | 18/737 | 157/18723 | 4.75e-05 | 1.21e-03 | 18 |
| GO:003410115 | Cervix | HSIL_HPV | erythrocyte homeostasis | 16/737 | 129/18723 | 4.76e-05 | 1.21e-03 | 16 |
| GO:004563913 | Cervix | HSIL_HPV | positive regulation of myeloid cell differentiation | 13/737 | 103/18723 | 2.00e-04 | 3.65e-03 | 13 |
| GO:001922111 | Cervix | HSIL_HPV | cytokine-mediated signaling pathway | 35/737 | 472/18723 | 2.64e-04 | 4.52e-03 | 35 |
| GO:003021815 | Cervix | HSIL_HPV | erythrocyte differentiation | 14/737 | 120/18723 | 2.67e-04 | 4.54e-03 | 14 |
| GO:004564811 | Cervix | HSIL_HPV | positive regulation of erythrocyte differentiation | 6/737 | 33/18723 | 1.63e-03 | 1.77e-02 | 6 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |